We know deals are due but the share price is stagnating, which seems surprising given that Craig is aiming to be a multi-billion dollar company. Perhaps punters are factoring in a CR since the 4c said there would be a CR:
"The Company anticipates that it will raise additional capital during the September 2022 quarter".
So, from the prospective investor's viewpoint, these are the short-term (by end of year) catalysts (up and down) that I'm seeing:
The first two would be sell the news (unless the CR was an investment at a premium which is unlikely prior to FDA approval) and the second two would be buy the news.
- Something from the $6.3m (USD) pipeline of deals
- CR from sophs or shareholders, or from debt funding
- FDA approval
- US listing
Any other catalysts? Also, does anyone know what it costs to list in the US?
General Forum, page-569
-
- There are more pages in this discussion • 1,142 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.88M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 265000 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 33080 | 1 |
View Market Depth
| Last trade - 16.12pm 12/09/2024 (20 minute delay) ? |
| CDX (ASX) Chart |
Day chart unavailable